Figure 1.

Lactoferrin (Lf) treatment increases body weight gain and rescues cognitive decline in amyloid precursor protein (APP)/presenilin 1 (PS1) mice. APP/PS1 transgenic (Tg) mice at the age of 6 months were treated with human Lf (hLf) (2 mg/kg per day or 6 mg/kg day) for 3 months before their body weights and cognitive abilities were evaluated. (a) The body weights of the mice were increased in the hLf-treated group relative to vehicle controls. (b) During MWM training from day 1 to day 2, the results of the visible platform tests did not differ among the groups, whereas the hLf-treated APP/PS1 mice showed a decrease in escape latency from the fifth day to the seventh day of testing in the hidden platform tests. (c) In the probe trial toward the target quadrant on the eighth day, the passing times of the mice in the hLf treatment group were significantly increased compared with the mice in the untreated group. (d) The motion tracking of the mice in the different groups is shown for the hidden platform tests. All values are the means±SEM (n=8). *p<0.05, **p<0.01 compared with the vehicle group.